Carboplatin/Cyclophosphamide vs. Cisplatin/ Cyclophosphamide in Patients with Measurable and Non- Measurable (Sub-Optimal) Disease Stages III and IV Ovarian Cancer

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

M Markman;M Federico;PY Liu;E Hannigan;D Alberts Gynecologic Oncology 103:195-198

Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment.

D Heddens;DS Alberts;EV Hannigan;SD Williams;D Garcia;DJ Roe;J Bell;RD Alvarez Gynecologic Oncology 86:239-243

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

DS Alberts;SJ Green;EV Hannigan;R O'Toole;D Stock-Novack;P Anderson;EA Surwit;VK Malvlya;WA Nahhas;CJ Jolles Classic Papers and Current Comments 7(1):41-52

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

DS Alberts;S Green;EV Hannigan;R O'Toole;D Stock-Novack;P Anderson;EA Surwit;VK Malvlya;WA Nahhas;CJ Jolles Classic Papers and Current Comments 3(1):145-157

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials.

DS Alberts;PY Liu British Journal of Cancer 78(11):1479-1487

CA-125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG) study.

PY Liu;DS Alberts;M Federico;EV Hannigan;DJ Garcia;ML Rothenberg;RT Dorr ASCO 14:266(#735)

Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis

DS Alberts;EV Hannigan;R Cannetta;R O'Toole;VK Malviya;EA Surwit;WA Nahhas;CJ Jolles;J Jacobs;S Pashko Pharmacy and Therapeutics 19(7):692-706

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.

DS Alberts;S Dahlberg;SJ Green;D Garcia;EV Hannigan;R O'Toole;D Stock-Novack;EA Surwit;VK Malviya;CJ Jolles Cancer 71(2):618-627

Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.

EV Hannigan;S Green;DS Alberts;R O'Toole;E Surwit Oncology 50(Suppl.2):2-9

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III (suboptimal) and IV ovarian cancer.

DS Alberts;S Green;EV Hannigan;R O'Toole;D Stock-Novack;P Anderson;EA Surwit;VK Malviya;WA Nahhas;CJ Jolles JCO 10(5):706-717

Chemotherapy in advanced ovarian cancer; an overview of randomized clinical trials. Advanced ovarian cancer trialists group.

British Medical Journal 303:884-893

Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Preliminary report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer.

DS Alberts;SJ Green;EV Hannigan;R O'Toole;N Mason-Liddil;EA Surwit;D Stock-Novack;R Goldberg;VK Malviya;WA Nahhas;RP Pugh;JT Guy;SR Dakhil Carboplatin Current Perspectives and Future Directions (JM-8):163-164

Assessment of treatment costs for carboplatin and cisplatin.

E Hannigan;D Alberts;S Green;R O'Toole;N Mason-Liddil;E Surwit;D Stock-Novack;R Goldberg;V Malviya;W Nahhas;R Canetta;R Thomas ASCO 9:337(#1305)

Relationship between serum CA-125 levels at chemotherapy courses 3 and 6 and the outcome of second-look surgery status in advanced ovarian cancer.

DS Alberts;PY Liu;E Hannigan;EA Surwit;J O'Sullivan;D Garcia;M Richardson;S Williams;J Young;R O'Toole AACR 31:189(#1121)

Improved efficacy of carboplatin (CarboP)/cyclophosphamide (CPA)vs cisplatin (CisP)/CPA: Preliminary report of a phase III, randomizedtrial in stages III-IV, suboptimal ovarian cancer (OVCA).

D Alberts;S Green;E Hannigan;R O'Toole;N Mason-Liddil;E Surwit;D Stock-Novack;R Goldberg;V Malviya;W Nahhas ASCO 8:151(#588)

Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: A Southwest Oncology Group study.

DS Alberts;N Mason;E Surwit;S Weiner;N Hammond;G Deppe Cancer Treat Rep 12(Suppl A):1-10

Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: A Southwest Oncology Group study.

DS Alberts;N Mason;E Surwit;S Weiner;N Hammond;G Deppe Proc ECCO, Interferon Alpha-2 Symposium, Stockholm, Sweden, June 19